In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
about
Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia).Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.Adenoviral Vectors for Hemophilia Gene TherapyReview--the use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product.Adeno-associated virus vectors and hematologyGene therapy for the hemophilias.Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organsGene therapy for hemophilia.In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene.Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo.Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B.Human parathyroid hormone is secreted primarily into the bloodstream after rat parotid gland gene transfer.Gene therapy for haemophilia.The role of progenitor cells in repair of liver injury and in liver transplantation.Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit modelProtein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivoAssessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers.Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells.Understanding hereditary diseases using the dog and human as companion model systems.Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver.Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.Large animal models and gene therapy.Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemiaA factor IX-deficient mouse model for hemophilia B gene therapy.Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A miceLong-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector.NFkappaB prevents apoptosis and liver dysfunction during liver regeneration.Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.Successful expression of human factor IX following repeat administration of adenoviral vector in mice.The function of dog models in developing gene therapy strategies for human health.Historical perspective and future direction of coagulation research.Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies.Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes.Coexpression of p21(WAF1/CIP1) in adenovirus vector transfected human primary hepatocytes prevents apoptosis resulting in improved transgene expression.Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage fluid.Future developments in the treatment of haemophilia B.
P2860
Q30659161-6956AD7B-429E-41FA-8F34-6EAFB16E4EA5Q33181472-CA972650-04DB-45A5-B8BC-78E6CE64DA45Q33690648-98E2288F-2581-4985-8F2A-4FF7D4837708Q33692535-7995B694-9338-4388-AA58-5C92F7E51640Q33695816-ADC70050-BB2E-4A0C-982E-6399A82DCCF7Q33723486-CE05F46B-2098-49EA-BC2A-A03426CF772BQ33817535-29C62ED5-68A2-4DDB-B497-69EA223DC857Q33838660-3FA40537-2A9C-4AA1-ACA6-150EE15E89BBQ34202163-6330AB1C-A0A2-4CA2-8D71-C05A17EA6EB9Q34203283-7881B2D9-BD94-4E21-B3A6-FBEE567BE9F2Q34343757-25EEA463-F16E-4C77-83A1-A463F00B4B09Q34511805-82B3B7E4-F44B-4682-B4CC-F8201686832CQ34530130-5EFC4DB2-9C7B-47AB-8987-D1E5CEFF379BQ34565292-7FEA1AC1-229C-41DB-89BC-9510B9583AFCQ34953097-74E85F60-F375-4BCB-AE35-0448E3091B0CQ35006603-022A4866-AB47-49EF-87CE-E1B633A0BE3FQ35149966-A5D54E76-0F02-411B-A252-FF373C9E8636Q35361567-03991058-F53C-4706-916C-DC269D060817Q35874183-2C6B3E3A-E702-43F7-BA97-C35C0457DE10Q35889029-5C5A8C86-1E0D-4AF1-AF84-DBDCA985B530Q36021334-EA66B2C5-572A-4851-8ADA-5F9AD16E50E7Q36145287-E0AAE3C6-E1F8-43DD-A1AD-F800A3DF357CQ36159178-063918AC-1A21-4A9F-8910-5647705069BEQ36310768-E7B2569E-C709-48A8-AF95-95678C430259Q36333340-7929A9CC-AD17-4417-9E0B-311D549EAA10Q36455873-8481EF3F-7C84-47CC-8EC8-5A9D6A6CA83BQ36602472-494C9DA5-9FDA-4DC2-B982-7FB139860AB5Q36843682-2765DD77-7F23-4711-B9CE-AF1854D78522Q37300572-7A0082C6-FFD9-4F3E-B32A-F16645323058Q37378197-9BFEB081-B1C7-4F74-A41A-5E1FFE1E5D88Q37383736-8376F7A7-E781-4168-B0EF-F881129874F9Q37685172-6AA3B8D4-865D-4B7C-8CBD-802B19EA1FFDQ37898045-DFD8B2F4-A905-4513-B50B-DD4E5EF656FEQ37903961-E2052ECE-C71E-4F2F-BC55-5325665768D0Q37950457-F84071D4-3036-47E3-81C0-27647D2133E9Q38754256-64052846-A2B6-4A95-9F63-5FBEB9C9BE4DQ39775108-1C55979D-AF0F-4941-B83E-30836957D581Q40655745-F7133518-ACA7-42F2-9F5A-29C24C1887B8Q40930997-D70028AC-8584-4FBB-888E-1BD87BACA1DDQ40998218-99DF73C3-520E-4F55-84DA-B8660C0985B4
P2860
In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
In vivo hepatic gene therapy: ...... ficiency in hemophilia B dogs.
@ast
In vivo hepatic gene therapy: ...... ficiency in hemophilia B dogs.
@en
type
label
In vivo hepatic gene therapy: ...... ficiency in hemophilia B dogs.
@ast
In vivo hepatic gene therapy: ...... ficiency in hemophilia B dogs.
@en
prefLabel
In vivo hepatic gene therapy: ...... ficiency in hemophilia B dogs.
@ast
In vivo hepatic gene therapy: ...... ficiency in hemophilia B dogs.
@en
P2093
P2860
P921
P356
P1476
In vivo hepatic gene therapy: ...... ficiency in hemophilia B dogs.
@en
P2093
A R Thompson
C N Landen
D Bellinger
L A Taylor
M Finegold
S R Rothenberg
P2860
P304
P356
10.1073/PNAS.91.6.2353
P407
P577
1994-03-01T00:00:00Z